BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34253930)

  • 1. A French cohort for assessing COVID-19 vaccine responses in specific populations.
    Loubet P; Wittkop L; Tartour E; Parfait B; Barrou B; Blay JY; Hourmant M; Lachâtre M; Laplaud DA; Laville M; Laviolle B; Lelievre JD; Morel J; Nguyen S; Spano JP; Terrier B; Thiebaut A; Viallard JF; Vrtovsnik F; de Lamballerie X; Launay O
    Nat Med; 2021 Aug; 27(8):1319-1321. PubMed ID: 34253930
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
    Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
    [No Abstract]   [Full Text] [Related]  

  • 3. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
    Edara VV; Pinsky BA; Suthar MS; Lai L; Davis-Gardner ME; Floyd K; Flowers MW; Wrammert J; Hussaini L; Ciric CR; Bechnak S; Stephens K; Graham BS; Bayat Mokhtari E; Mudvari P; Boritz E; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Douek DC; Sahoo MK; Sibai M; Solis D; Webby RJ; Jeevan T; Fabrizio TP
    N Engl J Med; 2021 Aug; 385(7):664-666. PubMed ID: 34233096
    [No Abstract]   [Full Text] [Related]  

  • 4. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
    Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
    Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.
    Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Cusi MG
    N Engl J Med; 2021 Jul; 385(1):90-92. PubMed ID: 33852796
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    Krammer F; Srivastava K; Alshammary H; Amoako AA; Awawda MH; Beach KF; Bermúdez-González MC; Bielak DA; Carreño JM; Chernet RL; Eaker LQ; Ferreri ED; Floda DL; Gleason CR; Hamburger JZ; Jiang K; Kleiner G; Jurczyszak D; Matthews JC; Mendez WA; Nabeel I; Mulder LCF; Raskin AJ; Russo KT; Salimbangon AT; Saksena M; Shin AS; Singh G; Sominsky LA; Stadlbauer D; Wajnberg A; Simon V
    N Engl J Med; 2021 Apr; 384(14):1372-1374. PubMed ID: 33691060
    [No Abstract]   [Full Text] [Related]  

  • 7. Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination.
    Abbasi J
    JAMA; 2021 Aug; 326(5):376-377. PubMed ID: 34259836
    [No Abstract]   [Full Text] [Related]  

  • 8. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
    Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
    N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.
    Edara VV; Hudson WH; Xie X; Ahmed R; Suthar MS
    JAMA; 2021 May; 325(18):1896-1898. PubMed ID: 33739374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns.
    Cassaniti I; Percivalle E; Zelini P; Ngaradoumbe Nanhorngue K; Parolo A; Bernardi V; Jorizzo G; Santer P; Perotti F; Spinillo A; Lilleri D; Baldanti F
    Clin Microbiol Infect; 2021 Nov; 27(11):1708-1709. PubMed ID: 34371204
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
    Doria-Rose N; Suthar MS; Makowski M; O'Connell S; McDermott AB; Flach B; Ledgerwood JE; Mascola JR; Graham BS; Lin BC; O'Dell S; Schmidt SD; Widge AT; Edara VV; Anderson EJ; Lai L; Floyd K; Rouphael NG; Zarnitsyna V; Roberts PC; Makhene M; Buchanan W; Luke CJ; Beigel JH; Jackson LA; Neuzil KM; Bennett H; Leav B; Albert J; Kunwar P;
    N Engl J Med; 2021 Jun; 384(23):2259-2261. PubMed ID: 33822494
    [No Abstract]   [Full Text] [Related]  

  • 12. Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.
    Joob B; Wiwanitkit V
    Clin Appl Thromb Hemost; 2021; 27():10760296211020833. PubMed ID: 34142570
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.
    Yi SG; Knight RJ; Graviss EA; Moore LW; Nguyen DT; Ghobrial RM; Gaber AO; Huang HJ
    Transplantation; 2021 Jul; 105(7):e72-e73. PubMed ID: 33741844
    [No Abstract]   [Full Text] [Related]  

  • 15. Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients.
    Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Edwards ESJ; Brooks AES
    Front Immunol; 2021; 12():798389. PubMed ID: 35116031
    [No Abstract]   [Full Text] [Related]  

  • 16. Audio Interview: Antibody Responses to Natural Infection and Vaccination.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Apr; 384(14):e65. PubMed ID: 33826826
    [No Abstract]   [Full Text] [Related]  

  • 17. The overlooked superpower of mRNA vaccines.
    Wadman M
    Science; 2021 Jul; 373(6554):479. PubMed ID: 34326217
    [No Abstract]   [Full Text] [Related]  

  • 18. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
    Terpos E; Trougakos IP; Gavriatopoulou M; Papassotiriou I; Sklirou AD; Ntanasis-Stathopoulos I; Papanagnou ED; Fotiou D; Kastritis E; Dimopoulos MA
    Blood; 2021 Jul; 137(26):3674-3676. PubMed ID: 33861315
    [No Abstract]   [Full Text] [Related]  

  • 19. Überantibodies From Recovered COVID-19 Patients Could Spur New Therapeutics and Vaccines.
    Abbasi J
    JAMA; 2021 Aug; 326(7):589-590. PubMed ID: 34319350
    [No Abstract]   [Full Text] [Related]  

  • 20. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination.
    Lippi G; Sciacovelli L; Trenti T; Plebani M;
    Clin Chem Lab Med; 2021 Jul; 59(8):1333-1335. PubMed ID: 33578505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.